Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus

• DOI: 10.1016/j.vaccine.2017.04.008
• Publication Date: 2017-04-14T06:16:52Z
• Authors: Trevor R.F. Smith; Katherine Schultheis; Matthew P. Morrow; Kimberly A. Kraynyak; Jay R. McCoy; Kevin C. Yim; Karuppiah Muthumani; Laurent Humeau; David B. Weiner; Niranjan Y. Sardesai; Kate E. Broderick
• Keywords: 0301 basic medicine; Respiratory Syncytial Virus Infections; 3. Good health; Disease Models, Animal; 03 medical and health sciences; Electroporation; Treatment Outcome; Respiratory Syncytial Virus Vaccines; Vaccines, DNA; Animals; Female; Sigmodontinae; Lung

Respiratory syncytial virus (RSV) is a massive medical burden in infants, children and the elderly worldwide, an effective, safe RSV vaccine remains unmet need. Here we assess novel vaccination strategy based on intradermal delivery of SynCon® DNA-based encoding engineered RSV-F antigen using surface electroporation device (SEP) to target epidermal cells, clinically relevant experimental models. We demonstrate ability this elicit robust immune responses. Importantly complete resistance pulmonary infection at single low dose cotton rat RSV/A challenge model. In contrast formalin-inactivated (FI-RSV) vaccine, there was no enhanced lung inflammation upon after DNA vaccination. summary data presented outline pre-clinical development highly efficacious, tolerable non-replicating strategy.